

Loreto Carmona

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4502831/publications.pdf>

Version: 2024-02-01

292
papers

32,055
citations

15504

65
h-index

4432

172
g-index

327
all docs

327
docs citations

327
times ranked

39673
citing authors

#	ARTICLE	IF	CITATIONS
1	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet</i> , The, 2012, 380, 2197-2223.	13.7	7,061
2	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet</i> , The, 2012, 380, 2163-2196.	13.7	6,376
3	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 859-866.	0.9	908
4	Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter activeâ€“surveillance report. <i>Arthritis and Rheumatism</i> , 2003, 48, 2122-2127.	6.7	889
5	The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1316-1322.	0.9	820
6	Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. <i>Arthritis and Rheumatism</i> , 2005, 52, 1766-1772.	6.7	612
7	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	0.9	496
8	The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 1040-1045.	0.9	487
9	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2010, 36, 1185-1206.	6.7	444
10	Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1086-1093.	0.9	404
11	EULAR recommendations for the management of familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 644-651.	0.9	393
12	Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. <i>Annals of the Rheumatic Diseases</i> , 2004, 64, 375-381.	0.9	379
13	Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. <i>Arthritis and Rheumatism</i> , 2007, 57, 756-761.	6.7	378
14	Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: Predictive value in disease activity and radiologic progression. <i>Arthritis and Rheumatism</i> , 2007, 57, 116-124.	6.7	342
15	European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1269-1274.	0.9	308
16	2018 update of the EULAR recommendations for the management of hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 16-24.	0.9	273
17	Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. <i>Arthritis Research and Therapy</i> , 2006, 8, R29.	3.5	250
18	Power doppler ultrasonographic monitoring of response to antiâ€“tumor necrosis factor therapy in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2248-2256.	6.7	245

#	ARTICLE	IF	CITATIONS
19	Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 935-942.	0.9	238
20	2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 8-13.	0.9	223
21	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 328-335.	0.9	222
22	The prevalence of rheumatoid arthritis in the general population of Spain. <i>British Journal of Rheumatology</i> , 2002, 41, 88-95.	2.3	205
23	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858.	0.9	204
24	All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 880-885.	0.9	196
25	Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 897-900.	0.9	194
26	The 2017 EULAR standardised procedures for ultrasound imaging in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1974-1979.	0.9	191
27	Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1680-1685.	0.9	190
28	Rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 733-745.	3.3	183
29	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 965-973.	0.9	179
30	Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1544-1549.	0.9	173
31	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , The, 2020, 2, e250-e253.	3.9	172
32	Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 177-182.	0.9	170
33	Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. <i>Arthritis Research and Therapy</i> , 2006, 8, R72.	3.5	167
34	A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 40, 2-14.e1.	3.4	161
35	Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. <i>Rheumatology</i> , 2007, 46, 1309-1315.	1.9	160
36	EULAR/PreS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 639-646.	0.9	157

#	ARTICLE	IF	CITATIONS
37	Costs and predictors of costs in rheumatoid arthritis: A prevalence-based study. Arthritis and Rheumatism, 2003, 49, 64-70.	6.7	155
38	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Annals of the Rheumatic Diseases, 2021, 80, 1137-1146.	0.9	151
39	Increased risk of tuberculosis in patients with rheumatoid arthritis. Journal of Rheumatology, 2003, 30, 1436-9.	2.0	150
40	Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. Arthritis and Rheumatology, 2017, 69, 1067-1077.	5.6	139
41	Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPtâ€“ a national health survey. RMD Open, 2016, 2, e000166.	3.8	133
42	Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology, 2014, 53, 1872-1885.	1.9	132
43	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Annals of the Rheumatic Diseases, 2022, 81, 695-709.	0.9	130
44	The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. Annals of the Rheumatic Diseases, 2015, 74, 1958-1967.	0.9	128
45	Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Metaâ€“Analysis. Arthritis and Rheumatology, 2015, 67, 117-127.	5.6	125
46	Multimorbidity: Prevalence, Effect on Quality of Life and Daily Functioning, and Variation of This Effect When one Condition Is a Rheumatic Disease. Seminars in Arthritis and Rheumatism, 2009, 38, 312-319.	3.4	124
47	2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. Annals of the Rheumatic Diseases, 2021, 80, 1278-1285.	0.9	124
48	Economic burden of knee and hip osteoarthritis in Spain. Arthritis and Rheumatism, 2009, 61, 158-165.	6.7	109
49	The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. Rheumatology, 2008, 47, 1088-1092.	1.9	100
50	Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Annals of the Rheumatic Diseases, 2017, 76, 1870-1882.	0.9	98
51	Cancer in Rheumatoid Arthritis: Occurrence, Mortality, and Associated Factors in a South European Population. Seminars in Arthritis and Rheumatism, 2008, 37, 388-397.	3.4	97
52	Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Annals of the Rheumatic Diseases, 2010, 69, 1751-1755.	0.9	96
53	Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists. Seminars in Arthritis and Rheumatism, 2011, 41, 71-80.	3.4	94
54	Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity, 2006, 39, 205-215.	2.6	93

#	ARTICLE	IF	CITATIONS
55	EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1596-1602.	0.9	87
56	Response to: "Correspondence on Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Mulhearn <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e116-e116.	0.9	87
57	Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2004, 31, 40-6.	2.0	87
58	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	5.9	86
59	Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 902-905.	0.9	82
60	The epidemiology of established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101477.	3.3	81
61	Systematic Review on the Effectiveness of Immunosuppressants and Biological Therapies in the Treatment of Autoimmune Posterior Uveitis. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 314-323.	3.4	76
62	Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 9-17.	3.4	76
63	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. <i>RMD Open</i> , 2019, 5, e001014.	3.8	73
64	Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. <i>Medicina Clínica</i> , 2011, 137, 533-540.	0.6	72
65	Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. <i>Autoimmunity Reviews</i> , 2011, 10, 383-388.	5.8	71
66	Efficacy and safety of non-pharmacological, pharmacological and surgical treatment for hand osteoarthritis: a systematic literature review informing the 2018 update of the EULAR recommendations for the management of hand osteoarthritis. <i>RMD Open</i> , 2018, 4, e000734.	3.8	71
67	Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 15-24.	0.9	68
68	Development of patient-centred standards of care for osteoarthritis in Europe: the eumusc.net-project. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1145-1149.	0.9	68
69	A two-stage approach to the treatment of hyperuricemia in gout: The "dirty dish" hypothesis. <i>Arthritis and Rheumatism</i> , 2011, 63, 4002-4006.	6.7	67
70	Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. <i>Rheumatology</i> , 2007, 47, 464-466.	1.9	65
71	High Sodium Intake Is Associated With Self-Reported Rheumatoid Arthritis. <i>Medicine (United States)</i> , 2015, 94, e0924.	1.0	64
72	Reduction of Bone Mass in Women after Bone Marrow Transplantation. <i>Calcified Tissue International</i> , 1997, 60, 343-347.	3.1	63

#	ARTICLE	IF	CITATIONS
73	Survival, Causes of Death, and Risk Factors Associated With Mortality in Spanish Systemic Sclerosis Patients: Results From a Single University Hospital. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 39, 285-293.	3.4	62
74	Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 382-385.	0.9	61
75	A meta-analysis of mortality in rheumatic diseases. <i>Reumatología Clínica</i> , 2012, 8, 334-341.	0.5	61
76	Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 524-533.	3.4	60
77	Efficacy and Safety of TNF Antagonists in Sarcoidosis: Data from the Spanish Registry of Biologics BIOBADASER and a Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 89-103.	3.4	59
78	Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. , 2005, , CD002229.		58
79	Systematic review and critical appraisal of transitional care programmes in rheumatology. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 372-379.	3.4	58
80	Prevalence of Vertebral Fractures by Semiautomated Morphometry in Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2011, 38, 893-897.	2.0	57
81	Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 44-52.	3.4	53
82	Cutaneous Adverse Events During Treatment of Chronic Inflammatory Rheumatic Conditions With Tumor Necrosis Factor Antagonists: Study Using the Spanish Registry of Adverse Events of Biological Therapies in Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2013, 65, 2024-2031.	3.4	52
83	Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. <i>Rheumatology International</i> , 2014, 34, 953-961.	3.0	50
84	Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 330-337.	3.4	49
85	Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 871-882.	0.9	49
86	Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. <i>RMD Open</i> , 2019, 5, e001015.	3.8	49
87	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.9	49
88	Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review. <i>Lupus</i> , 2015, 24, 1135-1142.	1.6	48
89	Predictors of rate of return to work after surgery for carpal tunnel syndrome. <i>Arthritis and Rheumatism</i> , 1998, 11, 298-305.	6.7	47
90	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 476-479.	0.9	47

#	ARTICLE	IF	CITATIONS
91	A Health System Program To Reduce Work Disability Related to Musculoskeletal Disorders. <i>Annals of Internal Medicine</i> , 2005, 143, 404.	3.9	46
92	Validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1350-1355.	0.9	46
93	Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. <i>Rheumatology International</i> , 2015, 35, 445-458.	3.0	46
94	Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1). <i>RMD Open</i> , 2021, 7, e001546.	3.8	46
95	Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. <i>Rheumatology</i> , 2011, 50, 1999-2004.	1.9	44
96	Assessing utility values in rheumatoid arthritis: A comparison between time trade-off and the EuroQol. <i>Arthritis and Rheumatism</i> , 2006, 55, 751-756.	6.7	43
97	Limited value of ultrasound assessment in patients with poor outcome after carpal tunnel release surgery. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 409-412.	1.1	42
98	Efficacy and safety of home-based exercises versus individualized supervised outpatient physical therapy programs after total knee arthroplasty: a systematic review and meta-analysis. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2017, 25, 3340-3353.	4.2	42
99	EULAR recommendations for intra-articular therapies. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1299-1305.	0.9	42
100	An Audit of the Variability of Diagnosis and Management of Gout in the Rheumatology Setting. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 349-355.	0.9	41
101	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e707-e714.	3.9	40
102	Transitional care for rheumatic conditions in Europe: current clinical practice and available resources. <i>Pediatric Rheumatology</i> , 2017, 15, 49.	2.1	39
103	Prevalence of Paget's disease of bone in Spain. <i>Bone</i> , 2008, 43, 1006-1009.	2.9	38
104	Predictors of treatment failure and mortality in native septic arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 1961-1967.	2.2	38
105	Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1263-1268.	0.9	38
106	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e855-e864.	3.9	38
107	A model for the development and implementation of a national plan for the optimal management of early spondyloarthritis: the Esperanza Program. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 827-830.	0.9	37
108	Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. <i>Rheumatology</i> , 2011, 50, 85-92.	1.9	36

#	ARTICLE	IF	CITATIONS
109	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.9	36
110	Patterns and Consequences of Multimorbidity in the General Population: There is No Chronic Disease Management Without Rheumatic Disease Management. <i>Arthritis Care and Research</i> , 2017, 69, 12-20.	3.4	36
111	Denosumab for the treatment of osteoporosis: A systematic literature review. <i>Reumatolog�a Cl�nica</i> , 2013, 9, 42-52.	0.5	35
112	Performance of the Assessment of Spondyloarthritis International Society criteria for the classification of spondyloarthritis in early spondyloarthritis clinics participating in the ESPERANZA programme. <i>Rheumatology</i> , 2014, 53, 353-360.	1.9	35
113	Trends towards improved disease state in Rheumatoid Arthritis over time: the influence of new therapies and changes in management approach: analysis of the EMECAR cohort. <i>Arthritis Research and Therapy</i> , 2008, 10, R138.	3.5	34
114	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	3.8	34
115	Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital. <i>Reumatolog�a Cl�nica</i> , 2014, 10, 89-93.	0.5	33
116	Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 126-132.	0.9	33
117	Prognostic factors in short-term disability due to musculoskeletal disorders. <i>Arthritis and Rheumatism</i> , 2008, 59, 489-496.	6.7	32
118	Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2003, 30, 697-704.	2.0	32
119	EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 840-847.	0.9	31
120	Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 559-69.	0.8	31
121	Observed and expected frequency of comorbid chronic diseases in rheumatic patients. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 418-421.	0.9	30
122	Musculoskeletal work disability for clinicians: Time course and effectiveness of a specialized intervention program by diagnosis. <i>Arthritis and Rheumatism</i> , 2007, 57, 335-342.	6.7	30
123	SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 145-150.	0.9	30
124	2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 707-713.	0.9	30
125	The Efficacy and Safety of Treatments for Acute Gout: Results from a Series of Systematic Literature Reviews Including Cochrane Reviews on Intraarticular Glucocorticoids, Colchicine, Nonsteroidal Antiinflammatory Drugs, and Interleukin-1 Inhibitors. <i>Journal of rheumatology Supplement</i> , The, 2014, 92, 15-25.	2.2	29
126	Is Spinal Mobility in Patients With Spondylitis Determined By Age, Structural Damage, and Inflammation?. <i>Arthritis Care and Research</i> , 2015, 67, 74-79.	3.4	29

#	ARTICLE	IF	CITATIONS
127	Weather conditions and their effect on seasonality of incident osteoporotic hip fracture. Archives of Osteoporosis, 2018, 13, 28.	2.4	29
128	Consensus of the Spanish society of pediatric rheumatology for transition management from pediatric to adult care in rheumatic patients with childhood onset. Rheumatology International, 2015, 35, 1615-1624.	3.0	28
129	Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. Rheumatology International, 2015, 35, 1127-1137.	3.0	28
130	Weather conditions may worsen symptoms in rheumatoid arthritis patients: The possible effect of temperature. Reumatología Clínica, 2013, 9, 226-228.	0.5	27
131	The burden of disease in Spain: results from the global burden of disease study 2010. BMC Medicine, 2014, 12, 236.	5.5	27
132	¿Se asocia la obesidad en la artritis psoriásica a una menor respuesta terapéutica y más efectos adversos con el tratamiento de fondo?. Reumatología Clínica, 2016, 12, 307-312.	0.5	27
133	Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study. Rheumatology International, 2017, 37, 1195-1202.	3.0	27
134	Management of the Psychological Impact of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 1492-1498.	1.9	27
135	Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study. Frontiers in Medicine, 2021, 8, 679009.	2.6	27
136	Burden of disease across chronic diseases: a health survey that measured prevalence, function, and quality of life. Journal of Rheumatology, 2008, 35, 159-65.	2.0	27
137	The EULAR Outcome Measures Library: an evolutionary database of validated patient-reported instruments. Annals of the Rheumatic Diseases, 2015, 74, 475-476.	0.9	26
138	EpiReumaPt- the study of rheumatic and musculoskeletal diseases in Portugal: a detailed view of the methodology. Acta Reumatológica Portuguesa, 2015, 40, 110-24.	0.2	26
139	Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain. Rheumatology International, 2017, 37, 1239-1248.	3.0	24
140	Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2725-2731.	3.8	24
141	Diferente expresión clínica de los pacientes con espondilitis anquilosante según el sexo en función del tiempo de evolución. Datos de REGISPONSER. Reumatología Clínica, 2013, 9, 221-225.	0.5	23
142	Orthopedic Surgery in Rheumatoid Arthritis in the Era of Biologic Therapy. Journal of Rheumatology, 2013, 40, 1850-1855.	2.0	23
143	Interleukin-1 inhibitors for acute gout. The Cochrane Library, 2014, 2014, CD009993.	2.8	23
144	Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider. RMD Open, 2020, 6, e001432.	3.8	23

#	ARTICLE	IF	CITATIONS
145	Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: Systematic review and meta-analysis of observational studies. <i>Joint Bone Spine</i> , 2014, 81, 41-50.	1.6	22
146	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. <i>Rheumatology</i> , 2015, 54, 1074-1079.	1.9	22
147	Disease Activity As a Major Determinant of Quality of Life and Physical Function in Patients With Early Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2017, 69, 150-155.	3.4	22
148	The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology. <i>Rheumatology International</i> , 2017, 37, 1227-1236.	3.0	22
149	Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1243-1252.	1.8	22
150	Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 423-430.	0.8	22
151	Consensus Statement of the Spanish Society of Rheumatology on Risk Management of Biologic Therapy in Rheumatic Patients. <i>Reumatología Clínica (English Edition)</i> , 2011, 7, 284-298.	0.3	21
152	Effectiveness of self-management interventions in inflammatory arthritis: a systematic review informing the 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. <i>RMD Open</i> , 2021, 7, e001647.	3.8	21
153	Prognostic factors for long-term work disability due to musculoskeletal disorders. <i>Rheumatology International</i> , 2012, 32, 3831-3839.	3.0	20
154	Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience. <i>Rheumatology International</i> , 2014, 34, 1059-1063.	3.0	19
155	Trends in osteoporotic hip fracture epidemiology over a 17-year period in a Spanish population: Alcorc 1999-2015. <i>Archives of Osteoporosis</i> , 2017, 12, 84.	2.4	19
156	El uso de abatacept en artritis reumatoide: revisión de la evidencia y recomendaciones. <i>Reumatología Clínica</i> , 2013, 9, 5-17.	0.5	18
157	Dietary supplements for chronic gout. <i>The Cochrane Library</i> , 2014, , CD010156.	2.8	18
158	Validation of a new objective index to measure spinal mobility: the University of Cordoba Ankylosing Spondylitis Metrology Index (UCOASMI). <i>Rheumatology International</i> , 2014, 34, 401-406.	3.0	18
159	Second Hip Fracture: Incidence, Trends, and Predictors. <i>Calcified Tissue International</i> , 2018, 102, 619-626.	3.1	18
160	Effectiveness of a clinical practice intervention in early rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 321-330.	3.4	17
161	Diagnostic Value of Clinical, Laboratory, and Imaging Findings in Patients with a Clinical Suspicion of Gout: A Systematic Literature Review. <i>Journal of rheumatology Supplement</i> , The, 2014, 92, 3-8.	2.2	16
162	Systematic review of systemic sclerosis-specific instruments for the EULAR Outcome Measures Library: An evolutionary database model of validated patient-reported outcomes. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 609-614.	3.4	16

#	ARTICLE	IF	CITATIONS
163	Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1291-1292.	0.9	16
164	Estudio sobre el manejo de la artritis reumatoide en España (emAR II). <i>Características clínicas de los pacientes. Reumatología Clínica</i> , 2012, 8, 236-242.	0.5	15
165	Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review. <i>Rheumatology International</i> , 2018, 38, 975-983.	3.0	15
166	Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews. <i>RMD Open</i> , 2021, 7, e001658.	3.8	15
167	Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 327-334.	0.9	15
168	Patient-physician collaboration in rheumatology: a necessity. <i>RMD Open</i> , 2017, 3, e000499.	3.8	14
169	Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practice. <i>Reumatología Clínica</i> , 2009, 5, 252-258.	0.5	13
170	Variabilidad en el consumo de recursos en pacientes con espondiloartritis en España. Datos descriptivos preliminares del estudio emAR II. <i>Reumatología Clínica</i> , 2012, 8, 114-9.	0.5	13
171	Índices compuestos para evaluar la actividad de la enfermedad y el daño estructural en pacientes con lupus eritematoso: revisión sistemática de la literatura. <i>Reumatología Clínica</i> , 2014, 10, 309-320.	0.5	13
172	Recomendaciones para la detección, investigación y derivación del dolor lumbar inflamatorio en Atención Primaria. <i>Reumatología Clínica</i> , 2015, 11, 90-98.	0.5	13
173	Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report. <i>Journal of Rheumatology</i> , 2017, 44, 1894-1898.	2.0	12
174	Are rheumatologists adhering to the concepts window of opportunity and treat-to-target? Earlier and more intense disease-modifying anti-rheumatic drug treatment over time in patients with early arthritis in the PEARL study. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 382-388.	0.8	12
175	Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative. <i>Journal of rheumatology Supplement</i> , The, 2011, 87, 54-58.	2.2	11
176	Development and Validation of a New Disease Activity Index as a Numerical Sum of Four Variables in Patients With Early Arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 518-525.	3.4	11
177	Is Obesity in Psoriatic Arthritis Associated With a Poorer Therapeutic Response and More Adverse Effects of Treatment With an Anchor Drug?. <i>Reumatología Clínica (English Edition)</i> , 2016, 12, 307-312.	0.3	11
178	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1423-1431.	0.9	11
179	The journey of the non-radiographic axial spondyloarthritis patient: the perspective of professionals and patients. <i>Clinical Rheumatology</i> , 2021, 40, 591-600.	2.2	11
180	Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0161727.	2.5	11

#	ARTICLE	IF	CITATIONS
181	Databases and registers: useful tools for research, no studies. Rheumatology International, 2014, 34, 447-452.	3.0	10
182	Validation of the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for systemic sclerosis in patients from a capillaroscopy clinic. Seminars in Arthritis and Rheumatism, 2016, 46, 350-355.	3.4	10
183	Barreras y facilitadores para la práctica del ejercicio físico en pacientes con espondiloartritis: estudio cualitativo de grupos focales (EJES-3D). Reumatología Clínica, 2017, 13, 91-96.	0.5	10
184	Diagnostic Value and Validity of Early Spondyloarthritis Features: Results From a National Spanish Cohort. Arthritis Care and Research, 2017, 69, 938-942.	3.4	10
185	The population impact of rheumatic and musculoskeletal diseases in relation to other non-communicable disorders: comparing two estimation approaches. Rheumatology International, 2018, 38, 905-915.	3.0	10
186	Facilitators to implement standards of care for rheumatoid arthritis and osteoarthritis: the EUMUSC.NET project. Annals of the Rheumatic Diseases, 2014, 73, 1545-1548.	0.9	9
187	Recomendaciones para la prescripción de ejercicio físico en pacientes con espondiloartritis. Reumatología Clínica, 2019, 15, 77-83.	0.5	9
188	Effect of an abdominal hypopressive technique programme on pelvic floor muscle tone and urinary incontinence in women: a randomised crossover trial. Physiotherapy, 2020, 108, 37-44.	0.4	9
189	How good is to switch between biologics? A systematic review of the literature. Acta Reumatológica Portuguesa, 2007, 32, 113-28.	0.2	9
190	Variability in Resource Consumption in Patients With Spondyloarthritis in Spain. Preliminary Descriptive Data From the emAR II Study. Reumatología Clínica (English Edition), 2012, 8, 114-119.	0.3	8
191	Factores motivadores y barreras para implantar una vía clínica de atención precoz de espondiloartritis: estudio cualitativo con médicos de atención primaria. Reumatología Clínica, 2013, 9, 85-89.	0.5	8
192	Incidence of Physical Disability Related to Musculoskeletal Disorders in the Elderly: Results From a Primary Care-Based Registry. Arthritis Care and Research, 2015, 67, 89-93.	3.4	8
193	Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological Progression in Tightly Controlled Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0166691.	2.5	8
194	The Challenge of Assessing Adherence to Subcutaneous Biological Drugs in Immune-Mediated Inflammatory Diseases. Letter to the Editor Regarding Michetti P, Weinman J, Mrowietz U, et al. Adv Ther (2017);34:91-108. doi:10.1007/s12325-016-0441-3. Advances in Therapy, 2017, 34, 2173-2176.	2.9	8
195	Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: A multinational real-world cohort analysis. Seminars in Arthritis and Rheumatism, 2022, 56, 152050.	3.4	8
196	Systematic review: Safety and efficacy of anti-TNF in elderly patients. Reumatología Clínica (English) 2020;26(10):100000. doi:10.1016/j.reuma.2020.100000. Overlock 10 TF	0.5	8
197	The practical value of biologics registries in Africa and Middle East: challenges and opportunities. Clinical Rheumatology, 2012, 31, 407-416.	2.2	7
198	Treatment Target and Followup Measures for Patients with Gout: A Systematic Literature Review. Journal of rheumatology Supplement, The, 2014, 92, 55-62.	2.2	7

#	ARTICLE	IF	CITATIONS
199	Recomendaciones para el manejo de la comorbilidad en la práctica clínica en pacientes con espondiloartritis axial. <i>Reumatología Clínica</i> , 2018, 14, 346-359.	0.5	7
200	2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 870-876.	3.4	7
201	Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 1164-1167.	2.0	7
202	Prevalence of silent amyloidosis in RA and its clinical significance. <i>Journal of Rheumatology</i> , 2004, 31, 1013-4; author reply 1014.	2.0	7
203	Quality-of-care standards for early arthritis clinics. <i>Rheumatology International</i> , 2013, 33, 2459-2472.	3.0	6
204	Weather conditions may worsen symptoms in rheumatoid arthritis patients: The possible effect of temperature. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 226-228.	0.3	6
205	Abatacept Use in Rheumatoid Arthritis: Evidence Review and Recommendations. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 5-17.	0.3	6
206	Tackling missing radiographic progression data: multiple imputation technique compared with inverse probability weights and complete case analysis. <i>Rheumatology</i> , 2013, 52, 331-336.	1.9	6
207	Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence. <i>Rheumatology International</i> , 2018, 38, 2289-2296.	3.0	6
208	Effect of Weight Loss on Activity in Psoriatic Arthritis: A Systematic Review. <i>Reumatología Clínica (English Edition)</i> , 2018, 14, 207-210.	0.3	6
209	High Reproducibility of an Automated Measurement of Mobility for Patients with Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2018, 45, 1383-1388.	2.0	6
210	Meta-analysis in the era of big data. <i>Clinical Rheumatology</i> , 2019, 38, 2027-2028.	2.2	6
211	Outcomes Reported in Prospective Long-term Observational Studies and Registries of Patients With Rheumatoid Arthritis Worldwide: An Outcome Measures in Rheumatology Systematic Review. <i>Arthritis Care and Research</i> , 2021, 73, 649-657.	3.4	6
212	EULAR COVID-19 registry: lessons learnt and future considerations. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1110-1115.	0.9	6
213	Patient's experiences of the barriers and facilitators to Methotrexate. <i>Musculoskeletal Care</i> , 2022, 20, 158-166.	1.4	6
214	Infections in Patients with Rheumatic Diseases Treated with TNF Antagonists. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1418-1425.	1.6	6
215	Intra-articular therapies: patient preferences and professional practices in European countries. <i>Rheumatology International</i> , 2022, 42, 869-878.	3.0	6
216	Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists. <i>Acta Reumatológica Portuguesa</i> , 2006, 31, 201-3.	0.2	6

#	ARTICLE	IF	CITATIONS
217	Quantifying risks: The case between glucocorticoids and tuberculosis. Arthritis and Rheumatism, 2006, 55, 1-2.	6.7	5
218	Management of Rheumatoid Arthritis in Spain (emAR II). Clinical Characteristics of the Patients. Reumatología Clínica (English Edition), 2012, 8, 236-242.	0.3	5
219	Recommendations for the Detection, Study and Referral of Inflammatory Low-back Pain in Primary Care. Reumatología Clínica (English Edition), 2015, 11, 90-98.	0.3	5
220	Aspectos prácticos de la medición de los niveles de fármacos biológicos y de anticuerpos antifármaco en artritis reumatoide y espondiloartritis. Reumatología Clínica, 2020, 16, 378-385.	0.5	5
221	Adverse Reactions Related to the Administration of TNF Inhibitors. Analysis of a Registry of Biologic Therapy. Reumatología Clínica (English Edition), 2008, 4, 90-95.	0.3	4
222	Despair on disparities. Annals of the Rheumatic Diseases, 2009, 68, 1657-1658.	0.9	4
223	Denosumab for the treatment of osteoporosis: A systematic literature review. Reumatología Clínica (English Edition), 2013, 9, 42-52.	0.3	4
224	Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: Three centers experience. Joint Bone Spine, 2013, 80, 438-440.	1.6	4
225	Is there a best way to measure co-morbidity?. Rheumatology, 2014, 53, 963-964.	1.9	4
226	Epidemiology of rheumatic and musculoskeletal diseases. Best Practice and Research in Clinical Rheumatology, 2018, 32, 167-168.	3.3	4
227	Discordance between doctor and patient assessments and non-adherence to subcutaneous biological drugs. Rheumatology International, 2019, 39, 1077-1082.	3.0	4
228	Satisfacción, cumplimiento de expectativas y adherencia al fármaco biológico subcutáneo en pacientes con artritis reumatoide. Estudio ARCO. Reumatología Clínica, 2020, 16, 116-119.	0.5	4
229	Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review. Immunotherapy, 2021, 13, 433-458.	2.0	4
230	Development of a patient-centered core domain set for prospective observational longitudinal outcome studies in rheumatoid arthritis: an OMERACT initiative. Seminars in Arthritis and Rheumatism, 2021, 51, 1113-1116.	3.4	4
231	Ensuring the Consistency of Biosimilars. Current Pharmaceutical Design, 2018, 23, 6733-6738.	1.9	4
232	Developing guidelines for ultrarare rheumatic disorders: a bumpy ride. Annals of the Rheumatic Diseases, 2022, 81, 1203-1205.	0.9	4
233	Anti-TNF therapy and cancer. Reumatología Clínica (English Edition), 2010, 6, 102-105.	0.3	3
234	Biobadaser 2.0: analysis and trends in 2009. Reumatología Clínica (English Edition), 2010, 6, 240-243.	0.3	3

#	ARTICLE	IF	CITATIONS
235	Characteristics of early arthritis units that may be associated with better referral efficiency: survey of SERAP units. <i>Reumatología Clínica (English Edition)</i> , 2011, 7, 236-240.	0.3	3
236	Clinical Composite Measures of Disease Activity for Diagnosis and Followup of Undifferentiated Peripheral Inflammatory Arthritis: A Systematic Review. <i>Journal of rheumatology Supplement</i> , The, 2011, 87, 48-53.	2.2	3
237	Reducing the Need for Central Dual-Energy X-Ray Absorptiometry in Postmenopausal Women: Efficacy of a Clinical Algorithm Including Peripheral Densitometry. <i>Calcified Tissue International</i> , 2013, 93, 62-68.	3.1	3
238	Consensus Statement on the Management of Comorbidity in Patients with Rheumatoid Arthritis and Psoriasis. <i>Journal of Rheumatology</i> , 2016, 43, 990-991.	2.0	3
239	Overview of changes in RMD epidemiology and outcome development in the last 10 years. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 169-173.	3.3	3
240	The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern. <i>Rheumatology International</i> , 2018, 38, 1735-1740.	3.0	3
241	Antisynthetase antibodies in clinical laboratories: the importance of clinical correlation and indirect immunofluorescence. Response to: Comment on: "Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria" by Greco et al by Knitza et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e87-e87.	0.9	3
242	Patients' perceptions on shared decision making during prescription of subcutaneous biological drug treatments for inflammatory arthritis: The RHEU-LIFE survey. <i>Musculoskeletal Care</i> , 2020, 18, 568-574.	1.4	3
243	Scoring with the Berlin MRI method for assessment of spinal inflammatory activity in patients with ankylosing spondylitis: a calibration exercise among rheumatologists. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 883-8.	0.8	3
244	More evidence on the dysautonomic nature of fibromyalgia: The association with short stature. <i>Arthritis and Rheumatism</i> , 2002, 46, 1415-1416.	6.7	2
245	What are patients with early rheumatoid arthritis like in Spain? Description of the PROAR cohort. <i>Reumatología Clínica (English Edition)</i> , 2009, 5, 115-120.	0.3	2
246	Assessment of multiple organ systems in systemic lupus erythematosus: what will the new guidelines mean?. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 291-297.	0.3	2
247	Diagnostic and Prognostic Value of Genetics in Undifferentiated Peripheral Inflammatory Arthritis: A Systematic Review. <i>Journal of rheumatology Supplement</i> , The, 2011, 87, 38-44.	2.2	2
248	A full new enthusiastic team. <i>Rheumatology International</i> , 2013, 33, 825-826.	3.0	2
249	Motivations and Objections to Implement a Spondyloarthritis Integrated Care Pathway. A Qualitative Study With Primary Care Physicians. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 85-89.	0.3	2
250	A10.24...Switching Infliximab for New Alternatives: A Correspondence Analysis of Biologics, Reasons to Stop, and Time Periods. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A80.3-A81.	0.9	2
251	Documento práctico para el uso de abatacept subcutáneo. <i>Reumatología Clínica</i> , 2014, 10, 218-226.	0.5	2
252	Clinical Composite Measures of Disease Activity and Damage Used to Evaluate Patients With Systemic Lupus Erythematosus: A Systematic Literature Review. <i>Reumatología Clínica (English Edition)</i> , 2014, 10, 309-320.	0.3	2

#	ARTICLE	IF	CITATIONS
253	Practice Guidelines for the Use of Subcutaneous Abatacept. <i>Reumatología Clínica (English Edition)</i> , 2014, 10, 218-226.	0.3	2
254	Epidemiology and health-related services. <i>Current Opinion in Rheumatology</i> , 2016, 28, 104-109.	4.3	2
255	The Ejes-3D tool for personalized prescription of exercise in axial spondyloarthritis through multimedia animations: pilot study. <i>Rheumatology International</i> , 2018, 38, 1277-1284.	3.0	2
256	Measuring inflammation in rheumatoid arthritis with a new clinical and ultrasound index: development and initial validation. <i>Rheumatology International</i> , 2019, 39, 2137-2145.	3.0	2
257	Facing arthritis: helping patients to handle their disease and concerns. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 903-905.	3.0	2
258	The comparative responsiveness of Hospital Universitario Princesa Index and other composite indices for assessing rheumatoid arthritis activity. <i>PLoS ONE</i> , 2019, 14, e0214717.	2.5	2
259	Perceptions of Patients With Rheumatic Diseases Treated With Subcutaneous Biologicals on Their Level of Information: RHEU-LIFE Survey. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 343-349.	0.3	2
260	Severity Indices in Rheumatoid Arthritis: A Systematic Review. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 146-151.	0.3	2
261	Recommendations for the Prescription of Physical Exercise for Patients With Spondyloarthritis. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 77-83.	0.3	2
262	Percepciones de los pacientes con enfermedades reumáticas tratados con biológicos subcutáneos sobre su nivel de información. Encuesta RHEU-LIFE. <i>Reumatología Clínica</i> , 2019, 15, 343-349.	0.5	2
263	Interobserver reliability of Masei index validation by a multicenter collaborative group of rheumatologists. <i>Rheumatology International</i> , 2020, , 1.	3.0	2
264	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Arnaud and Devilliers. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e114-e114.	0.9	2
265	Disease Activity Indices in Rheumatoid Arthritis: Comparative Performance to Detect Changes in Function, IL-6 Levels, and Radiographic Progression. <i>Frontiers in Medicine</i> , 2021, 8, 669688.	2.6	2
266	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Rosenbaum et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e139-e139.	0.9	2
267	Reducing bureaucracy in clinical trials, now is the time!. <i>RMD Open</i> , 2022, 8, e002202.	3.8	2
268	A meta-analysis of mortality in rheumatic diseases. <i>Reumatología Clínica (English Edition)</i> , 2012, 8, 334-341.	0.3	1
269	Le facteur rhumatoïde ne semble pas prédire la réponse aux anti-TNF \pm dans la polyarthrite rhumatoïde: expérience de trois centres. <i>Revue Du Rhumatisme (Edition Française)</i> , 2013, 80, 527-528.	0.0	1
270	An early intervention program for subacute physical disability related to musculoskeletal diseases in the elderly: a pilot study. <i>Rheumatology International</i> , 2015, 35, 1183-1191.	3.0	1

#	ARTICLE	IF	CITATIONS
271	Centre characteristics determine ambulatory care and referrals in patients with spondyloarthritis. Rheumatology International, 2016, 36, 1515-1523.	3.0	1
272	PROMs for Fibromyalgia. , 2016, , 175-208.		1
273	Restless farewell. Rheumatology International, 2017, 37, 1601-1602.	3.0	1
274	Recommendations for the Management of Comorbidity in Patients With Axial Spondyloarthritis in Clinical Practice. ReumatologĀa ClĀnica (English Edition), 2018, 14, 346-359.	0.3	1
275	Launch and preliminary analysis of Hospital de La Princesa's inter-specialists biological therapies unit. ReumatologĀa ClĀnica, 2019, 15, 63-68.	0.5	1
276	Āndices de gravedad en la artritis reumatoide: una revisi3n sistemĀtica. ReumatologĀa ClĀnica, 2019, 15, 146-151.	0.5	1
277	Practical aspects of biological throught levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis. ReumatologĀa ClĀnica (English Edition), 2020, 16, 378-385.	0.3	1
278	Satisfaction, fulfillment of expectations and adherence to subcutaneous biological drugs in patients with rheumatoid arthritis: ARCO study. ReumatologĀa ClĀnica (English Edition), 2020, 16, 116-119.	0.3	1
279	Revisi3n sistemĀtica del uso de metotrexato por vĀa parenteral en enfermedades reumĀticas. ReumatologĀa ClĀnica, 2021, , .	0.5	1
280	Prospective multicentre study of experience in real-world clinical practice in monitoring reported outcome measures (PROMs) of patient with a diagnosis of psoriatic and/or spondyloarthritis and initiating treatment with secukinumab. ReumatologĀa ClĀnica (English Edition), 2021, 18, 25-29.	0.3	1
281	Dietary supplements for chronic gout. The Cochrane Library, 2022, 2022, CD010156.	2.8	1
282	Patient perspectives on long-term outcomes in rheumatoid arthritis. A qualitative study from the OMERACT patient outcomes in longitudinal studies working group. Seminars in Arthritis and Rheumatism, 2023, 58, 152028.	3.4	1
283	Characteristics of Paget's disease in Spain. Data from the National Paget's Register. ReumatologĀa ClĀnica (English Edition), 2009, 5, 109-114.	0.3	0
284	Interleukin-1 inhibitors for chronic gout. The Cochrane Library, 0, , .	2.8	0
285	Centre-related variability in hospital admissions of patients with spondyloarthritis. Rheumatology International, 2016, 36, 1301-1308.	3.0	0
286	Launch and Preliminary Analysis of Hospital de La Princesa's Inter-specialists Biological Therapies Unit. ReumatologĀa ClĀnica (English Edition), 2019, 15, 63-68.	0.3	0
287	CaracterĀsticas epidemiol3gicas y eventos adversos de los pacientes con artritis psoriĀsica en tratamiento con terapias biol3gicas en Galicia. ReumatologĀa ClĀnica, 2021, 17, 150-154.	0.5	0
288	Epidemiological characteristics and adverse events of patients with psoriatic arthritis undergoing treatment with biological therapies in Galicia. ReumatologĀa ClĀnica (English Edition), 2021, 17, 150-154.	0.3	0

#	ARTICLE	IF	CITATIONS
289	Relation of the Serum Levels of DKK-1 and Osteoprotegerin with Bone Mass in Tightly Controlled Rheumatoid Arthritis. Current Rheumatology Reviews, 2021, 17, 101-108.	0.8	0
290	Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey. Joint Bone Spine, 2021, 88, 105172.	1.6	0
291	More, none, less therapeutic effect? Should we start talking about a "lessebo"™ effect?. Rheumatology, 2022, 61, 486-487.	1.9	0
292	Predicting Toxicity: Biomarkers and the Value of the Patient's Opinion. Current Pharmaceutical Design, 2014, 21, 233-240.	1.9	0